Publications by authors named "Chris Proffitt"

Claim this Profile
D
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1.
Mark Sabat, Daniel W Carney, Gloria Hernandez-Torres, Tony S Gibson, Deepika Balakrishna, Chris Proffitt

J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times.
Petro Halkowycz, Charles E Grimshaw, Walter Keung, Paul Tanis, Chris Proffitt

SLAS Discov· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Joshua Bliesath, Nanni Huser, Mayuko Omori, Daniel Bunag, Chris Proffitt

Cancer Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.
Mustapha Haddach, Michael K Schwaebe, Jerome Michaux, Johnny Nagasawa, Sean E O'Brien, Chris Proffitt

ACS Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Nadine Hein, Abigail Peck, Chris Proffitt

Cancer Cell· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser, Chris Proffitt

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.
Mustapha Haddach, Jerome Michaux, Michael K Schwaebe, Fabrice Pierre, Sean E O'Brien, Chris Proffitt

ACS Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.
Denis Drygin, Caroline B Ho, Mayuko Omori, Joshua Bliesath, Chris Proffitt

Biochem Biophys Res Commun· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Fabrice Pierre, Peter C Chua, Sean E O'Brien, Adam Siddiqui-Jain, Pauline Bourbon, Chris Proffitt

Mol Cell Biochem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Denis Drygin, Amy Lin, Josh Bliesath, Caroline B Ho, Sean E O'Brien, Chris Proffitt

Cancer Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Fabrice Pierre, Peter C Chua, Sean E O'Brien, Adam Siddiqui-Jain, Pauline Bourbon, Chris Proffitt

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner, Peter Chua, Fabrice Pierre, Chris Proffitt

Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Denis Drygin, Adam Siddiqui-Jain, Sean O'Brien, Michael Schwaebe, Amy Lin, Chris Proffitt

Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis